Pulling SEC filings + quote and writing the call…
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.63M | $5.21M | $3.89M | $0.00 | $0.00 | $18.7M | $2.33M | $886K | $0.00 | $0.00 |
| Revenue growth | — | 12.5% | -25.3% | -100.0% | — | — | -87.6% | -62.0% | -100.0% | — |
| Operating income | -$21.9M | -$27.7M | -$45.5M | -$80.3M | -$81.5M | -$65.6M | -$84.8M | -$242M | -$209M | -$210M |
| Operating margin | -473.3% | -531.7% | -1169.3% | — | — | -350.3% | -3640.2% | -27348.0% | — | — |
| Net income | -$21.7M | -$27.2M | -$44.3M | -$78.3M | -$80.9M | -$65.8M | -$83.8M | -$339M | -$208M | -$155M |
| Net margin | -468.8% | -523.3% | -1140.6% | — | — | -351.1% | -3598.8% | -38238.1% | — | — |
| EPS (diluted) | -$2.22 | -$1.80 | -$2.13 | -$2.45 | -$1.52 | -$25.02 | -$24.86 | -$49.12 | — | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.8M | -$24.6M | -$32.2M | -$65.7M | -$75.8M | -$53.7M | -$80.1M | -$99.9M | -$157M | -$169M |
| Capital expenditures | $212K | $619K | $422K | $1.49M | $4.28M | $573K | $38.0K | $0.00 | $0.00 | — |
| Free cash flow | -$19.1M | -$25.2M | -$32.6M | -$67.2M | -$80.1M | -$54.3M | -$80.2M | -$99.9M | -$157M | — |
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $47.7M | $12.8M | $22.5M | $19.3M | $90.1M | $15.1M | $34.9M | $189M | $89.4M | $85.7M |
| Total assets | $67.1M | $56.1M | $77.7M | $83.2M | $162M | $110M | $71.1M | $342M | $608M | $778M |
| Total liabilities | $4.10M | $5.74M | $10.3M | $23.1M | $21.8M | $26.0M | $20.8M | $73.3M | $90.7M | $62.5M |
| Shareholders' equity | $63.0M | $50.3M | $67.4M | $60.1M | $140M | $83.9M | $50.3M | $184M | $518M | $715M |
| Retained earnings | -$45.3M | -$72.5M | -$117M | -$195M | -$276M | -$342M | -$426M | -$764M | -$972M | -$1.13B |
| Shares (wtd avg diluted) | 13.4M | 16.7M | 24.1M | 29.1M | 48.0M | 49.4M | 2.61M | 36.1M | 60.3M | 78.2M |
Every figure is extracted from Spyre Therapeutics, Inc.’s annual reports as filed with the SEC (XBRL company facts) — no third-party estimates. Fiscal years are labeled by period end; filers occasionally re-tag concepts, so a sparse cell means the company didn’t report that concept for that year. Free cash flow = operating cash flow − capital expenditures.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.